secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001829126-25-000863
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zeo ScientifiX update: Phase I Zofin trial complete, PPX revenue up $474K, partnerships expanded
--------------------------------------------------------------------------------

- Completed Phase I safety trials for flagship Zofin; plans to amend INDs for Phase II targeting Osteoarthrosis and COPD.
- PPX autologous product revenue increased by approximately $474,000 in FY2024 compared to prior fiscal year.
- Issued patents for amniotic fluid processing techniques and PPX blood-derived exosome pain treatment method in past year.
- Strategic partnership with Physicians Group LLC, operating 75 clinics and 750 clinicians, for collaborative research and clinical trials.
- Launched ZEO HAIR GROW topical product with Exotropin; aims at hair loss market affecting 35M men and 31M women in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912625000863/0001829126-25-000863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912625000863/zeoscientifix_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-000863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer